Immuron 과거 수익 실적

과거 기준 확인 0/6

Immuron은 연평균 2.5%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 13%의 비율로 수입이 증가했습니다. 매출은 연평균 11.4%의 비율로 증가했습니다.

주요 정보

2.5%

수익 성장률

10.8%

EPS 성장률

Biotechs 산업 성장	9.6%
매출 성장률	11.4%
자기자본 수익률	-54.6%
순이익	-141.5%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Immuron 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

ASX:IMC 수익, 비용 및 수입 (AUD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	5	-7	7	5
31 Mar 24	4	-5	6	5
31 Dec 23	4	-4	6	4
30 Sep 23	3	-4	5	3
30 Jun 23	2	-4	5	3
31 Mar 23	1	-3	5	2
31 Dec 22	1	-3	4	2
30 Sep 22	1	-3	4	1
30 Jun 22	1	-3	4	1
31 Mar 22	1	-4	4	1
31 Dec 21	0	-4	4	1
30 Sep 21	0	-6	5	1
30 Jun 21	0	-8	6	1
31 Mar 21	1	-8	6	1
31 Dec 20	1	-7	6	1
30 Sep 20	2	-5	5	1
30 Jun 20	3	-3	4	1
31 Mar 20	3	-4	5	1
31 Dec 19	3	-5	6	1
30 Sep 19	3	-5	6	1
30 Jun 19	2	-5	6	1
31 Mar 19	2	-4	5	1
31 Dec 18	2	-3	4	1
30 Sep 18	2	-3	4	2
30 Jun 18	2	-3	4	2
31 Mar 18	2	-4	4	3
31 Dec 17	2	-5	5	4
30 Sep 17	2	-6	5	4
30 Jun 17	1	-7	5	5
31 Mar 17	1	-8	5	4
31 Dec 16	1	-6	5	4
30 Sep 16	1	-6	5	4
30 Jun 16	1	-7	5	4
31 Mar 16	1	-5	4	4
31 Dec 15	1	-4	3	4
30 Sep 15	1	-4	3	4
30 Jun 15	1	-3	2	3
31 Mar 15	1	-3	2	2
31 Dec 14	1	-2	1	2
30 Sep 14	1	-2	1	2
30 Jun 14	1	-2	2	1
31 Mar 14	1	-3	2	1
31 Dec 13	0	-3	2	1

양질의 수익: IMC 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IMC 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IMC 은(는) 수익성이 없지만 지난 5년 동안 연간 2.5% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 IMC 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IMC 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 2.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: IMC 현재 수익성이 없기 때문에 마이너스 자본 수익률( -54.58% )을 갖습니다.

Immuron 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.85

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기